Table 1.
Clinical trials involving HMG-CoA reductase inhibitors and reporting both carotid IMT and cardiovascular event outcomes.
| Clinical Trial (N*) | Statin | Relative Impact on IMT Progression of Primary Outcome (mm/yr): Mean [95% CI] (reported p-value) | Relative Impact on Reported Cardiovascular Endpoints: Odds Ratio [95% CI] | |
| Abstracted CVD Event | Odds Ratio | |||
| ACAPS(25) (N = 919) | Lovastatin | -0.015 [-0.023, -0.007] (p = 0.001) | CVD Death, MI, Stroke | 0.34 [0.12, 0.69] |
| KAPS(26) (N = 447) | Pravastatin | -0.014 [-0.022, -0.006] (p = 0.005) | CVD Death, MI, Stroke | 0.57 [0.22, 1.47] |
| PLAC-II(47) (N = 151) | Pravastatin | -0.009 [-0.031, 0.013] (p = 0.44) | Clinical Coronary Events | 0.37 [0.11, 1.24] |
| CAIUS(48) (N = 305) | Pravastatin | -0.014 [-0.021, -0.005] (p = 0.0007) | CVD Death, MI | 1.02 [0.14, 7.33] |
| REGRESS(28) (N = 255) | Pravastatin | -0.030 [-0.056, -0.004] (p = 0.002) | Clinical Events | 0.51 [0.24, 1.07] |
| BCAPS(49) (N = 793) | Fluvastatin | -0.008 [-0.013, -0.003] (p = 0.002) | CVD Death, MI, Stroke | 0.64 [-0.24, 1.66] |
| FAST(50) (N = 164) | Pravastatin | Significant Benefit (p < 0.001) | CVD Death, MI | 0.32 [0.10, 1.06] |
| Pooled Estimate | -0.012 [-0.016, -0.007]** | 0.48 [0.30, 0.78] | ||
*Arms used in meta-analysis; **Excludes FAST